A Transgenic Mouse Model to Study Ebolaviruses and other Filoviruses
研究埃博拉病毒和其他丝状病毒的转基因小鼠模型
基本信息
- 批准号:10038454
- 负责人:
- 金额:$ 20.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-22 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AfricanAnimal ModelAntiviral AgentsBiologicalBreedingBundibugyo virusCase Fatality RatesCell Culture TechniquesCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChickensChinaChiropteraCollaborationsContainmentDefective VirusesDemocratic Republic of the CongoDendritic CellsDevelopmentDiseaseDisease OutbreaksDisseminated Intravascular CoagulationEbolaEbola virusEngineeringEvaluationFailureFamilyFibroblastsFilovirusFutureGenomeGlycoproteinsGoalsGrowthGuineaHematopoieticHistopathologyHumanImmune responseImmunologicsIn VitroInfectionKenyaKineticsKnock-inLaboratoriesLaboratory ResearchLife Cycle StagesLiverMessenger RNAModelingMorphologyMusNatureOrganPTPRC genePathogenesisPathogenicityPhenotypePropertyProteinsPublic HealthRegulationResearchResearch PersonnelResistanceReston Ebola virusRiskScience PolicySierra LeoneSpainSudan Ebola virusSystemTailTherapeuticTherapeutic AgentsTimeTrainingTransgenic AnimalsTransgenic MiceTransgenic OrganismsUnited States National Institutes of HealthUniversitiesVaccinesViralViral GenesViral GenomeVirulence FactorsVirusVirus ReplicationWild Type MouseWisconsinZaire Ebola virusbasebeta Actincell typecostdisease phenotypeforestgenome editinghuman diseasein vivoinsightmacrophagemembermonocytemouse modelpathogenic viruspromoterresearch and developmentsafety testingstable cell linetherapeutic vaccine
项目摘要
PROJECT SUMMARY
Ebola viruses and other members of the filovirus family cause severe and often lethal infections. While some
progress has been made in regards to the development of experimental countermeasures and insights into the
highly pathogenic nature of these viruses, there are still many more unanswered questions, and further
advancement is needed towards the development of pan-filovirus therapeutic agents and vaccines. A significant
hurdle to research on filoviruses is the accessibility and cost associated with high-containment, biosafety level-
4 laboratories. To partially alleviate this issue, we previously established a replication-defective Ebola virus
based on the Zaire ebolavirus (EBOV) genome. This virus, which lacks the essential viral gene VP30 (termed
EBOVΔVP30), is biologically inert and safe to use outside of highly specialized BSL-4 containment. In
engineered cell lines that stably express EBOV VP30, the virus becomes replication-competent; thus it is a
perfect EBOV surrogate for in vitro research given that EBOVΔVP30 resembles authentic virus in its life cycle,
morphology, protein composition, and growth kinetics. After extensive safety testing both in cell culture and in
animal models, the CDC and the Office of Science Policy at the NIH classified EBOVΔVP30 as a BSL-2 agent
and removed the virus from Select Agent regulations. Since then, this in vitro system to study EBOV has been
requested by and distributed to several other research laboratories.
The next step to advance the EBOVΔVP30 system is to develop an EBOV VP30 transgenic animal model to
support virus replication. Previously, we generated a transgenic mouse line that expressed EBOV VP30 under
the control of the chicken beta-actin promoter (CAG). Although we were able to detect VP30 mRNA in key
organs, such as the liver, and functional VP30 protein in cells, such as fibroblasts, we were unable to detect
VP30 mRNA and functional protein in monocyte-derived macrophages, the first target of EBOV infection and a
cell type essential for virus dissemination throughout the body. Here, we propose to generate a new transgenic
mouse line with EBOV VP30 expression under the control of the CD45 promoter, a promoter specific for
expression in hematopoietic cells, including monocytes, macrophages, and dendritic cells. Once we confirm the
expression and function of VP30 in these cell types, particularly macrophages, we will cross our two different
VP30 transgenic lines (CAG and CD45) to generate a double knock-in transgenic mouse line. Once established,
we will infect these transgenic mice with mouse-adapted EBOVΔVP30 and characterize the phenotype. We will
also generate chimeric versions of EBOVΔVP30 with glycoproteins from other filoviruses and examine the
phenotype of these chimeric viruses in the transgenic mice. After safety testing, this new small animal model will
be an ideal in vivo surrogate for the authentic mouse model for EBOV infection. For the first time, a transgenic
mouse model will be available that can be used efficiently and safely outside of BSL-4 containment to examine
EBOV pathogenesis and accelerate the development and evaluation of countermeasures.
项目总结
埃博拉病毒和丝状病毒家族的其他成员会导致严重的、往往是致命的感染。虽然有些人
在制定试验性对策和对
这些病毒的高致病性,仍然有很多悬而未决的问题,而且进一步
需要在开发泛丝状病毒治疗剂和疫苗方面取得进展。一个重要的
丝状病毒研究的障碍是与高遏制、生物安全水平相关的可及性和成本-
4个实验室。为了部分缓解这个问题,我们之前建立了复制缺陷埃博拉病毒
基于扎伊尔埃博拉病毒(EBOV)基因组。这种病毒缺乏必要的病毒基因VP30(称为
EBOVBSL VP30)是生物惰性的,在高度专业的Δ-4安全壳外使用是安全的。在……里面
稳定表达EBOV VP30的工程细胞系,病毒变得具有复制能力;因此,它是一种
鉴于eBOVΔVP30在其生命周期中与真实病毒相似,因此是体外研究的完美替代品,
形态、蛋白质组成和生长动力学。经过广泛的安全测试,在细胞培养和
动物模型、疾病预防控制中心和国立卫生研究院科学政策办公室将EBVΔVP30归类为BSL-2毒剂
并从选择代理条例中删除了该病毒。从那时起,这种体外系统一直在研究EBOV
应其他几个研究实验室的要求并分发给其他几个研究实验室。
EBOVVP30系统的下一步进展是建立一种EBOVVP30转基因动物模型,以
支持病毒复制。此前,我们建立了一个表达EBOV VP30的转基因小鼠系
鸡β-肌动蛋白启动子(CAG)的调控。尽管我们能够在KEY中检测到VP30基因
器官,如肝脏,以及细胞中的功能性VP30蛋白,如成纤维细胞,我们无法检测到
单核细胞来源的巨噬细胞中VP30的mRNA和功能蛋白,EBOV感染的第一个靶点和
病毒在全身传播所必需的细胞类型。在这里,我们建议产生一种新的转基因
EBOV VP30小鼠品系在CD45启动子的控制下表达,是一种特异性的启动子
在造血细胞中表达,包括单核细胞、巨噬细胞和树突状细胞。一旦我们确认了
VP30在这些细胞类型中的表达和功能,特别是巨噬细胞,我们将跨越我们的两个不同的
用VP30转基因系(CAG和CD45)建立双敲入转基因小鼠系。一旦建立起来,
我们将用小鼠适应的EB病毒ΔVP30感染这些转基因小鼠,并对其表型进行鉴定。我们会
还用来自其他丝状病毒的糖蛋白生成嵌合版本的EBVΔVP30,并检查
这些嵌合病毒在转基因小鼠中的表型。经过安全测试,这种新的小动物模型将
可作为EBOV感染小鼠模型的理想体内替代物。第一次,转基因生物
将提供可在BSL-4安全壳外高效、安全地使用的鼠标模型,以进行检查
并加速EBOV发病机制的制定和评价对策。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOSHIHIRO KAWAOKA其他文献
YOSHIHIRO KAWAOKA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOSHIHIRO KAWAOKA', 18)}}的其他基金
Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
- 批准号:
10821572 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
- 批准号:
10359831 - 财政年份:2021
- 资助金额:
$ 20.66万 - 项目类别:
Development of broadly-protective vaccines for influenza B viruses
开发针对乙型流感病毒的广泛保护性疫苗
- 批准号:
10206685 - 财政年份:2021
- 资助金额:
$ 20.66万 - 项目类别:
COVID-19 comorbidity studies in Syrian hamster models
叙利亚仓鼠模型中的 COVID-19 合并症研究
- 批准号:
10450889 - 财政年份:2021
- 资助金额:
$ 20.66万 - 项目类别:
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
PanCorVac(泛冠状病毒疫苗开发中心)
- 批准号:
10841731 - 财政年份:2021
- 资助金额:
$ 20.66万 - 项目类别:
COVID-19 comorbidity studies in Syrian hamster models
叙利亚仓鼠模型中的 COVID-19 合并症研究
- 批准号:
10285154 - 财政年份:2021
- 资助金额:
$ 20.66万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists